NCT04184115View on ClinicalTrials.gov

Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness

PHASE3CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

June 9, 2019

Primary Completion Date

June 11, 2019

Study Completion Date

June 11, 2019

Conditions
Motion Sickness
Interventions
DRUG

DPI-386 Nasal Gel

1.5 mg reservoir of scopolamine to be delivered over a 72-hour period

DRUG

Placebos

Placebo Nasal Gel and placebo patch

Trial Locations (1)

90806

Collaborative Neuroscience Network, LLC, Long Beach

All Listed Sponsors
lead

Repurposed Therapeutics, Inc.

INDUSTRY

NCT04184115 - Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness | Biotech Hunter | Biotech Hunter